Why did TFFP's Q2 2024 earnings outperform forecasts so dramatically?

TFFP's Q2 2024 earnings outperformed forecasts due to **Roth Capital's Increased Earnings Estimates**. Roth Capital analyst J. Aschoff increased his Q2 2024 earnings estimates for TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) in a report issued on May 15, 2024. Aschoff now anticipates that the company will post earnings of ($1.70) per share for the quarter, up from their previous forecast of ($2.11). This increase in earnings estimates reflects a more optimistic outlook for TFFP's performance in Q2 2024 compared to the previous expectations.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|TFFP|TFFP.O|TFF Pharmaceuticals|2023 Q4|35.409428210199216|-4762414|186|
|TFFP|TFFP.O|TFF Pharmaceuticals|2024 Q1|18.66621039579985|-5735144|186|
|TFFP|TFFP.O|TFF Pharmaceuticals|2024 Q2|10.776151416894047|-4479221|186|
|TFFP|TFFP.O|TFF Pharmaceuticals|2024 Q3|19.6022492744788|-3544933|186|

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|TFFP|TFFP.O|TFF Pharmaceuticals|2023 Q4|-63.4477907794616|114328|186|
|TFFP|TFFP.O|TFF Pharmaceuticals|2024 Q1|295.2497618075405|203273|186|
|TFFP|TFFP.O|TFF Pharmaceuticals|2024 Q2|95.05626201811303|650222|186|
|TFFP|TFFP.O|TFF Pharmaceuticals|2024 Q3|-17.62458309018031|193387|186|

|code|Ticker|Name|Date|Net Income|market_code|
|---|---|---|---|---|---|
|TFFP|TFFP.O|TFF Pharmaceuticals|2023 Q4|-4762414|186|
|TFFP|TFFP.O|TFF Pharmaceuticals|2024 Q1|-5735144|186|
|TFFP|TFFP.O|TFF Pharmaceuticals|2024 Q2|-4479221|186|
|TFFP|TFFP.O|TFF Pharmaceuticals|2024 Q3|-3544933|186|